All stock lists
Lichen International Limited (NASDAQ:LICN)
CN · Delayed Price · Currency is USD
Industrials · Specialty Business Services
0.32-0.20 (-38.28%)
Market cap
$5.11M
Insider Score
Health Score
Listed since
Feb 6, 2023
Website
Insider Score
––Not scored
LICN Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From LICN’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $58.2M
- Net income
- -$40.4M
- Net margin
- -69.5%
Leverage20 / 20
Little or no net debt.
- Total debt
- $304K
- Cash
- $19.6M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $24.6M
- Current liabilities
- $4.2M
- Current ratio
- 5.81
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$32.9M
- Free cash flow
- -$27.1M
- FCF margin
- -46.7%
Dilution & runway1 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 16.3M
- Share growth (1y)
- 9.8%
- Cash runway
- 7 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
LICN Income Statement
| Fiscal Period | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Dec 31, 2025 | Jun 30, 2025 | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 |
| Revenue | 10.26 M | 10.26 M | 14.26 M | 23.38 M | 18.10 M | 23.83 M |
| Revenue Growth (YoY) | -43.28 % | -56.96 % | -10.46 % | 32.43 % | 12.05 % | 37.70 % |
| Cost of Revenue | 8.72 M | 7.72 M | 7.67 M | 8.67 M | 7.13 M | 9.34 M |
| Gross Profit | 1.55 M | 2.54 M | 6.59 M | 14.71 M | 10.96 M | 14.49 M |
| SG&A Expense | 10.27 M | 11.70 M | 11.84 M | 20.96 M | 9.26 M | 5.08 M |
| R&D Expense | 0.00 | 0.00 | 0.00 | 1.38 M | 0.00 | 1.19 M |
| Operating Expenses | 10.27 M | 11.70 M | 11.84 M | 20.96 M | 9.26 M | 5.07 M |
| Operating Income | -8.72 M | -9.16 M | -5.25 M | -6.25 M | 1.70 M | 9.41 M |
| Pretax Income | -11.54 M | -12.69 M | -9.09 M | -5.94 M | 1.77 M | 9.44 M |
| Tax Provision | 13.00 K | -88.00 K | 88.00 K | 948.00 K | 1.00 M | 2.45 M |
| Net Income | -11.55 M | -12.61 M | -9.36 M | -6.91 M | 767.00 K | 6.98 M |
| EPS (Basic) | -0.71 | -0.77 | -0.60 | -0.46 | 0.05 | 0.26 |
| EPS (Diluted) | -0.71 | -0.77 | -0.60 | -0.46 | 0.05 | 0.26 |
| Shares Outstanding | 16.33 M | 16.33 M | 15.60 M | 14.87 M | 14.87 M | 26.51 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.